

DAFTAR PUSTAKA

- Al-Momany, N.H., Makahleh, Z.M., Al-Omari, N.A., Al-Sarayreh, H.A., and Momani, R.O., 2019, Analysis of Factors That Interrupt With INR Control in the First Anticoagulation Clinic Monitoring Jordanian Patients, *Clin. Appl. Thromb.*, 25, .
- Alshammari, A., Altuwayjiri, A., Alshaharani, Z., Bustami, R., and Almodaimegh, H.S., 2020, Warfarin Dosing Requirement According to Body Mass Index, *Cureus*, 12, 10–13.
- Amin, A., Houmsse, A., Ishola, A., Tyler, J., and Houmsse, M., 2016, The current approach of atrial fibrillation management, *Avicenna J. Med.*, 06, 8–16.
- Aronow, W.S., 2019, Medical management after myocardial infarction, *Future Cardiol.*, 15, 135–138.
- Barnes, G.D., 2020, Combining antiplatelet and anticoagulant therapy in cardiovascular disease, *Hematol. (United States)*, 20, 642–648.
- Buddeke, J., Bots, M.L., Van Dis, I., Visseren, F.L.J., Hollander, M., Schellevis, F.G., and Vaartjes, I., 2019, Comorbidity in patients with cardiovascular disease in primary care: A cohort study with routine healthcare data, *Br. J. Gen. Pract.*, 69, E398–E406.
- Chen, W.C., Chen, Y.H., Hsu, P.I., Tsay, F.W., Chan, H.H., Cheng, J.S., and Lai, K.H., 2014, Gastrointestinal hemorrhage in warfarin anticoagulated patients: Incidence, risk factor, management, and outcome, *Biomed Res. Int.*, 2014, .
- Dang, M.T.N., Hambleton, J., and Kayser, S.R., 2005, The influence of ethnicity on warfarin dosage requirement, *Ann. Pharmacother.*, 39, 1008–1012.
- Delgado, G.E., Zirlik, A., Gruber, R., Scheffold, T., Krämer, B.K., März, W., and Kleber, M.E., 2019, The association of high-normal international-normalized-ratio (INR) with mortality in patients referred for coronary angiography, *PLoS One*, 14, 1–14.
- Donaldson, C.J. and Harrington, D.J., 2017, Therapeutic warfarin use and the extrahepatic functions of vitamin K-dependent proteins, *Br. J. Biomed. Sci.*, 74, 163–169.
- Elango, K., Javaid, A., Khetarpal, B.K., Ramalingam, S., Kolandaivel, K.P., Gunasekaran, K., and Ahsan, C., 2021, The effects of warfarin and direct oral anticoagulants on systemic vascular calcification: A review, *Cells*, 10, 1–14.
- Engell, A.E., Svendsen, A.L.O., Lind, B.S., Andersen, C.L., Andersen, J.S., Willadsen, T.G., Persson, F., and Pottegård, A., 2021, Drug-drug interaction between warfarin and statins: A Danish cohort study, *Br. J. Clin. Pharmacol.*, 87, 694–699.
- Fawzy, A.M. and Lip, G.Y.H., 2019, Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation, *Expert Opin. Drug Metab.*

Toxicol., 15, 381–398.

Frańk, W., Wojtasińska, A., Lisińska, W., Młynarska, E., Franczyk, B., and Rysz, J., 2022, Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease, *Biomedicines*, 10, .

Fuchs, F.D. and Whelton, P.K., 2020, High Blood Pressure and Cardiovascular Disease, *Hypertension*, 75, 285–292.

Gomes, T., Mamdani, M.M., Holbrook, A.M., Paterson, J.M., Hellings, C., and Juurlink, D.N., 2013, Rates of hemorrhage during warfarin therapy for atrial fibrillation, *C. Can. Med. Assoc. J.*, 185, 121–127.

Health, Q., 2016, Guidelines for warfarin management in the community Guidelines for Warfarin Management in the Community Guidelines for warfarin management in the community -iii, *Dep. Heal.*, 1–27.

Jimenez-Ruiz, A., Gutierrez-Castillo, A., and Ruiz-Sandoval, J.L., 2018, Fatal Intracranial Hemorrhage Associated with Oral Warfarin Use, *Cureus*, 10, .

Kahlon, P., Nabi, S., Arshad, A., Jabbar, A., and Haythem, A., 2016, Hiperkoagulabilite durumları olan hastalarda terapötik uluslararası düzeltme oranına ulaşmak için gerekli warfarin doz ve süresi, *Turkish J. Hematol.*, 33, 299–303.

Kim, J.Y., Kim, S.H., Myong, J.P., Kim, Y.R., Kim, T.S., Kim, J.H., Jang, S.W., Oh, Y.S., Lee, M.Y., and Rho, T.H., 2019, Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis, *J. Am. Coll. Cardiol.*, 73, 1123–1131.

Knapp, S., 2014, Risk Rating :,5, 1–4.

Kumano, O., Akatsuchi, K., and Amiral, J., 2021, Updates on anticoagulation and laboratory tools for therapy monitoring of heparin, vitamin k antagonists and direct oral anticoagulants, *Biomedicines*, 9, .

Lee, K.K., Doudesis, D., Bing, R., Astengo, F., Perez, J.R., Anand, A., McIntyre, S., Bloor, N., Sandler, B., Lister, S., Pollock, K.G., Qureshi, A.C., McAllister, D.A., Shah, A.S.V., and Mills, N.L., 2023, Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study, *J. Am. Heart Assoc.*, 12, .

Lilik, N.I.S. and Budiono, I., 2021, Risiko Kematian Pasien Gagal Jantung Kongestif (GJK): Studi Kohort Retrospektif Berbasis Rumah Sakit, *Indones. J. Public Heal. Nutr.*, 1, 388–395.

Mak, M., Lam, C., Pineda, S.J., Lou, M., Xu, L.Y., Meeks, C., Lin, C., Stone, R., Rodgers, K., and Mitani, G., 2019, Pharmacogenetics of Warfarin in a Diverse Patient Population, *J. Cardiovasc. Pharmacol. Ther.*, 24, 521–533.

Martes-martinez, C., French-kim, M., Giselle, C., Duconge-soler, J., Juan, S., Rico,

- P., Campus, M.S., Juan, S., Rico, P., Service, P., Juan, S., Rico, P., Campus, S., Juan, S., and Rico, P., 2018, Affiliated Anticoagulation Clinic of Puerto Rico, *36*, 165–172.
- McKenzie, J.A., Wilson-Clarke, C., Prout, J., Campbell, J., Douglas, R.D., and Gossell-Williams, M., 2018, Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica, *Pharm. Pract. (Granada)*, *16*, 1–5.
- Mohamed, S., Mei Fong, C., Jie Ming, Y., Naila Kori, A., Abdul Wahab, S., and Mohd Ali, Z., 2021, Evaluation of an Initiation Regimen of Warfarin for International Normalized Ratio Target 2.0 to 3.0, *J. Pharm. Technol.*, *37*, 286–292.
- Morris, R., Todd, M., Aponte, N.Z., Salcedo, M., Bruckner, M., Garcia, A.S., Webb, R., Bu, K., Han, W., and Cheng, F., 2023, The association between warfarin usage and international normalized ratio increase: systematic analysis of FDA Adverse Event Reporting System (FAERS), *J. Cardiovasc. Aging*, *3*, .
- Nelson, W.W., Desai, S., Damaraju, C. V., Lu, L., Fields, L.E., Wildgoose, P., and Schein, J.R., 2015, International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation, *Am. J. Cardiovasc. Drugs*, *15*, 205–211.
- Nicklas, J.M., Gordon, A.E., and Henke, P.K., 2020, Resolution of deep venous thrombosis: Proposed immune paradigms, *Int. J. Mol. Sci.*, *21*, 1–24.
- Nilamsari, W.P., Hamdani, I.Y., Suprapti, B., Alsagaff, M.Y., Yogiarto, M., and Suharjono, 2023, Challenges in Achieving Optimal Warfarin Anticoagulation Control: A Comprehensive Exploration and Proposed Holistic Approach, *Indones. J. Pharm.*, *34*, 665–674.
- Ning, X., Kuang, Y., Yang, G., Xie, J., Miao, D., Guo, C., and Huang, Z., 2021, Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial, *Naunyn. Schmiedebergs. Arch. Pharmacol.*, *394*, 1275–1283.
- Ningrum, V.D.A., Sufiyah, Widyastuti, I.D., Yusuf, B.S., and Dullah, W., 2020, Bleeding incidence in patients administered with warfarin at secondary hospitals in Yogyakarta province, *Indones. J. Pharm.*, *31*, 217–228.
- Octasari, P.M. and Silvianingsih, N., 2022, Kesesuaian Nilai Inr (International Normalized Ratio) Pasien Kardiovaskuler Dengan Terapi Warfarin Di Poli Spesialis Jantung Rs Roemani Muhammadiyah Semarang, *Cendekia J. Pharm.*, *6*, 46–54.
- Online, L., 2023, ALERT: US Boxed Warning Brand Names: Canada Pharmacologic Category Dosing: Adult, *Lexi- drug*, 1–22.
- Orlando Regional Medical Center, 2009, Warfarin Dosing Guideline, *Therapy*, 3–

7.

- Ozturk, M., Ipekci, A., Kiyak, S.K., Akdeniz, Y.S., Aydin, Y., Ikizceli, I., and Sogut, O., 2019, Bleeding Complications in Warfarin-Treated Patients Admitted to the Emergency Department, *J. Clin. Med. Res.*, 11, 106–113.
- Papala, M., Gillard, D., Hardman, J., Romano, T., and Rein, L.E., 2022, Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic, *J. Thromb. Thrombolysis*, 53, 626–632.
- Parakh, N., Math, R.S., and Chaturvedi, V., 2018, Mitral Stenosis, *Mitral Stenosis*, 1–367.
- Piechocki, M., Przewłocki, T., Pieniążek, P., Trystuła, M., Podolec, J., and Kabłak-Ziembicka, A., 2024, A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review: Part I—Epidemiology, Risk Factors, and Atherosclerosis-Related Diversities in Elderly Patients, *J. Clin. Med.*, 13, .
- Pourdeyhimi, N. and Bullard, Z., 2014, Warfarin-induced skin necrosis, *Hosp. Pharm.*, 49, 1044–1048.
- Priksri, W., Rattanavipanon, W., Saejear, W., Tanyasaensook, K., Phrommintikul, A., Chulavatnatol, S., and Nathisuwan, S., 2019, Incidence, risk factors, and outcomes of warfarin-associated major bleeding in Thai population, *Pharmacoepidemiol. Drug Saf.*, 28, 942–950.
- Putriana, N.A., Rusdiana, T., Rostinawati, T., Akbar, M.R., and Destiani, D.P., 2022, Evaluation of Warfarin Use in Cardiac Clinic Outpatients, *Pharmacol. Clin. Pharm. Res.*, 7, 40.
- Raccach, B.H., Perlman, A., Zwas, D.R., Hochberg-Klein, S., Masarwa, R., Muszkat, M., and Matok, I., 2018, Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis, *Ann. Pharmacother.*, 52, 1135–1142.
- Rahmawati, F., Aulia, I.A.A., and Pramantara, I.D.P., 2022, Profil Klinis Pasien Pengguna Warfarin Pada Poli Jantung RSUD Dr. Soeselo Kabupaten Tegal, *Maj. Farm.*, 18, 201–210.
- Rohla, M., Weiss, T.W., Pecen, L., Patti, G., Siller-Matula, J.M., Schnabel, R.B., Schilling, R., Kotecha, D., Lucerna, M., Huber, K., De Caterina, R., and Kirchhof, P., 2019, Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: The prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF), *BMJ Open*, 9, 1–8.
- Rydberg, D.M., Linder, M., Malmström, R.E., and Andersen, M., 2020, Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication, *Eur. J. Clin. Pharmacol.*, 76, 867–876.

- Ryu, R. and Tran, R., 2022, DOACs in Mechanical and Bioprosthetic Heart Valves: A Narrative Review of Emerging Data and Future Directions, *Clin. Appl. Thromb.*, 28, .
- Sayhan, M.B., Oğuz, S., Yüksel, V., Hüseyin, S., Sayhan, E.S., and Yağcı, G., 2014, The Analysis of Patients Admitted to the Emergency Department Due to Complications Related to Warfarin Treatment, 194–198.
- Shakoor, H., Platat, C., Ali, H.I., Ismail, L.C., Al Dhaheri, A.S., Bosevski, M., Apostolopoulos, V., and Stojanovska, L., 2023, The benefits of physical activity in middle-aged individuals for cardiovascular disease outcomes, *Maturitas*, 168, 49–52.
- Shendre, A., Parmar, G.M., Dillon, C., Beasley, T.M., and Limdi, N.A., 2018, Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage, *Pharmacotherapy*, 38, 588–596.
- Sombat, B., Tongkaew, S., Nilwananon, A., Mungthin, M., Jongcherdchootrakul, K., and Lertwanichwattana, T., 2023, Incidence and risk factors of warfarin therapy complications in community hospitals, central and eastern regions, Thailand: a retrospective, multicenter, cohort study, *BMC Res. Notes*, 16, 4–11.
- Sonuga, B.O., Hellenberg, D.A., Cupido, C.S., and Jaeger, C., 2021, Profile And Anticoagulation Outcomes Of Patients On Warfarin Therapy In An Urban Hospital In Cape Town, South Africa, *African J. Prim. Heal. Care Fam. Med.*, 8, 1–8.
- Steiner, T., Weitz, J.I., and Veltkamp, R., 2017, Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents, *Stroke*, 48, 1432–1437.
- Suwanawiboon, B., Rotchanapanya, W., Mahaprom, K., Thongnoppakhun, W., Lalerd, Y., Limwongse, C., Sermsathanasawadi, N., and Owattanapanich, W., 2022, The efficacy of low-dose warfarin initiation (3 mg versus 5 mg) in newly diagnosed venous thromboembolism patients among a population with a high prevalence of warfarin-sensitive haplotype of the VKORC1 gene: a randomized controlled trial, *Hematol. (United Kingdom)*, 27, 95–104.
- Tideman, P.A., Tirimacco, R., and John, A.S., 2016, Correction: How to manage warfarin therapy [Correction], *Aust. Prescr.*, 39, 66.
- Tomaselli, G.F., Mahaffey, K.W., Cuker, A., Dobesh, P.P., Doherty, J.U., Eikelboom, J.W., Florido, R., Gluckman, T.J., Hucker, W.J., Mehran, R., Messé, S.R., Perino, A.C., Rodriguez, F., Sarode, R., Siegal, D.M., and Wiggins, B.S., 2020, 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants, *J. Am. Coll. Cardiol.*, 76, 594–622.
- Wang, M., Zeraatkar, D., Obeda, M., Lee, M., Garcia, C., Nguyen, L., Agarwal, A.,

- Al-Shalabi, F., Benipal, H., Ahmad, A., Abbas, M., Vidug, K., and Holbrook, A., 2021, Drug–drug interactions with warfarin: A systematic review and meta-analysis, *Br. J. Clin. Pharmacol.*, 87, 4051–4100.
- Wells, G.A., Elliott, J., Kelly, S., Bai, Z., Boucher, M., Skidmore, B., So, D., Laplante, S., and Lee, K., 2019, Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration, *Dual Antiplatelet Ther. Follow. Percutaneous Coron. Interv. Clin. Econ. Impact Stand. Versus Ext. Durat.*, 9, .
- Xiang, D., Liu, Y., Zhou, S., Zhou, E., and Wang, Y., 2021, Protective Effects of Estrogen on Cardiovascular Disease Mediated by Oxidative Stress, *Oxid. Med. Cell. Longev.*, 2021, .
- Yamagishi, S.I., 2019, Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation, *Cardiovasc. Diabetol.*, 18, 18–21.
- Yusuf, S., Amir, A., Jackie, B., Joseph, P., Lonn, E., McCready, T., Mente, A., Nieuwlaat, R., Pais, P., Rodgers, A., Schwalm, J.D., Smith, R., Teo, K., and Xavier, D., 2014, Combination pharmacotherapy to prevent cardiovascular disease: Present status and challenges, *Eur. Heart J.*, 35, 353–364.
- Zainuddin, A.A., Oendari, A., Putri, A., Pamungkas, A., Natsir, B., Hartono, D., Hariyani, I., Hendarto, J., Sitepu, M.S., Putri, N.P., and Salinah;, 2014, Panduan Praktik Klinis Bagi Dokter, *Ikat. Dr. Indones.*, 483.